These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28860329)

  • 1. Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A.
    Fledrich R; Mannil M; Leha A; Ehbrecht C; Solari A; Pelayo-Negro AL; Berciano J; Schlotter-Weigel B; Schnizer TJ; Prukop T; Garcia-Angarita N; Czesnik D; Haberlová J; Mazanec R; Paulus W; Beissbarth T; Walter MC; Triaal C; Hogrel JY; Dubourg O; Schenone A; Baets J; De Jonghe P; Shy ME; Horvath R; Pareyson D; Seeman P; Young P; Sereda MW
    J Neurol Neurosurg Psychiatry; 2017 Nov; 88(11):941-952. PubMed ID: 28860329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients.
    Fledrich R; Schlotter-Weigel B; Schnizer TJ; Wichert SP; Stassart RM; Meyer zu Hörste G; Klink A; Weiss BG; Haag U; Walter MC; Rautenstrauss B; Paulus W; Rossner MJ; Sereda MW
    Brain; 2012 Jan; 135(Pt 1):72-87. PubMed ID: 22189569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PMP22 messenger RNA levels in skin biopsies: testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker.
    Nobbio L; Visigalli D; Radice D; Fiorina E; Solari A; Lauria G; Reilly MM; Santoro L; Schenone A; Pareyson D;
    Brain; 2014 Jun; 137(Pt 6):1614-20. PubMed ID: 24812204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients.
    Mannil M; Solari A; Leha A; Pelayo-Negro AL; Berciano J; Schlotter-Weigel B; Walter MC; Rautenstrauss B; Schnizer TJ; Schenone A; Seeman P; Kadian C; Schreiber O; Angarita NG; Fabrizi GM; Gemignani F; Padua L; Santoro L; Quattrone A; Vita G; Calabrese D; ; Young P; Laurà M; Haberlová J; Mazanec R; Paulus W; Beissbarth T; Shy ME; Reilly MM; Pareyson D; Sereda MW
    Neuromuscul Disord; 2014 Nov; 24(11):1003-17. PubMed ID: 25085517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma metabolome and skin proteins in Charcot-Marie-Tooth 1A patients.
    Soldevilla B; Cuevas-Martín C; Ibáñez C; Santacatterina F; Alberti MA; Simó C; Casasnovas C; Márquez-Infante C; Sevilla T; Pascual SI; Sánchez-Aragó M; Espinos C; Palau F; Cuezva JM
    PLoS One; 2017; 12(6):e0178376. PubMed ID: 28575008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble Neuregulin1 is strongly up-regulated in the rat model of Charcot-Marie-Tooth 1A disease.
    Fornasari BE; Ronchi G; Pascal D; Visigalli D; Capodivento G; Nobbio L; Perroteau I; Schenone A; Geuna S; Gambarotta G
    Exp Biol Med (Maywood); 2018 Feb; 243(4):370-374. PubMed ID: 29350067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies.
    Svaren J; Moran JJ; Wu X; Zuccarino R; Bacon C; Bai Y; Ramesh R; Gutmann L; Anderson DM; Pavelec D; Shy ME
    Ann Neurol; 2019 Jun; 85(6):887-898. PubMed ID: 30945774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT): A Protocol to Address Clinical Trial Readiness in CMT1A.
    Eichinger K; Sowden JE; Burns J; McDermott MP; Krischer J; Thornton J; Pareyson D; Scherer SS; Shy ME; Reilly MM; Herrmann DN
    Front Neurol; 2022; 13():930435. PubMed ID: 35832173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropathy progression in Charcot-Marie-Tooth disease type 1A.
    Shy ME; Chen L; Swan ER; Taube R; Krajewski KM; Herrmann D; Lewis RA; McDermott MP
    Neurology; 2008 Jan; 70(5):378-83. PubMed ID: 18227419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.
    Gess B; Baets J; De Jonghe P; Reilly MM; Pareyson D; Young P
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011952. PubMed ID: 26662471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs as Biomarkers of Charcot-Marie-Tooth Disease Type 1A.
    Wang H; Davison M; Wang K; Xia TH; Call KM; Luo J; Wu X; Zuccarino R; Bacha A; Bai Y; Gutmann L; Feely SME; Grider T; Rossor AM; Reilly MM; Shy ME; Svaren J
    Neurology; 2021 Aug; 97(5):e489-e500. PubMed ID: 34031204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombination hot spot in a 3.2-kb region of the Charcot-Marie-Tooth type 1A repeat sequences: new tools for molecular diagnosis of hereditary neuropathy with liability to pressure palsies and of Charcot-Marie-Tooth type 1A. French CMT Collaborative Research Group.
    Lopes J; LeGuern E; Gouider R; Tardieu S; Abbas N; Birouk N; Gugenheim M; Bouche P; Agid Y; Brice A
    Am J Hum Genet; 1996 Jun; 58(6):1223-30. PubMed ID: 8651299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motor performance deterioration accelerates after 50 years of age in Charcot-Marie-Tooth type 1A patients.
    Tozza S; Bruzzese D; Pisciotta C; Iodice R; Esposito M; Dubbioso R; Ruggiero L; Topa A; Spina E; Santoro L; Manganelli F
    Eur J Neurol; 2018 Feb; 25(2):301-306. PubMed ID: 29053907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Employment status of patients with Charcot-Marie-Tooth type 1A.
    Bjelica B; Brankovic M; Bozovic I; Palibrk A; Kacar A; Rakocevic-Stojanovic V
    Acta Neurol Belg; 2022 Jun; 122(3):641-646. PubMed ID: 33491123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased severity over generations of Charcot-Marie-Tooth disease type 1A.
    Steiner I; Gotkine M; Steiner-Birmanns B; Biran I; Silverstein S; Abeliovich D; Argov Z; Wirguin I
    J Neurol; 2008 Jun; 255(6):813-9. PubMed ID: 18438698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin Biopsy Findings in Patients With CMT1A: Baseline Data From the CLN-PXT3003-01 Study Provide New Insights Into the Pathophysiology of the Disorder.
    Duchesne M; Danigo A; Richard L; Vallat JM; Attarian S; Gonnaud PM; Lacour A; Péréon Y; Stojkovic T; Nave KA; Bertrand V; Nabirotchkin S; Cohen D; Demiot C; Magy L
    J Neuropathol Exp Neurol; 2018 Apr; 77(4):274-281. PubMed ID: 29408953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative assessment of muscle echogenicity in Charcot-Marie-Tooth disease type 1A by automatic thresholding methods.
    Kitaoji T; Noto YI; Kojima Y; Tsuji Y; Mizuno T; Nakagawa M
    Clin Neurophysiol; 2021 Oct; 132(10):2693-2701. PubMed ID: 34294566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NCAM1 and GDF15 are biomarkers of Charcot-Marie-Tooth disease in patients and mice.
    Jennings MJ; Kagiava A; Vendredy L; Spaulding EL; Stavrou M; Hathazi D; Grüneboom A; De Winter V; Gess B; Schara U; Pogoryelova O; Lochmüller H; Borchers CH; Roos A; Burgess RW; Timmerman V; Kleopa KA; Horvath R
    Brain; 2022 Nov; 145(11):3999-4015. PubMed ID: 35148379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Charcot-Marie-Tooth disease and related inherited neuropathies.
    Murakami T; Garcia CA; Reiter LT; Lupski JR
    Medicine (Baltimore); 1996 Sep; 75(5):233-50. PubMed ID: 8862346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of comorbidities on the phenotype of patients affected by Charcot-Marie-Tooth neuropathy type 1A.
    Ursino G; Alberti MA; Grandis M; Reni L; Pareyson D; Bellone E; Gemelli C; Sabatelli M; Pisciotta C; Luigetti M; Santoro L; Massollo L; Schenone A
    Neuromuscul Disord; 2013 Nov; 23(11):902-6. PubMed ID: 23891256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.